title: Should aspirin be used for primary prevention of thrombotic events in patients with membranous nephropathy?
abstract: Patients with nephrotic syndrome are at increased risk of thrombosis. The risk of venous thrombosis is particularly high in patients with nephrotic syndrome due to primary membranous nephropathy. Recent data provide evidence that these patients also have a high absolute risk of arterial thrombotic events, which is associated with the degree of hypoalbuminemia. In this commentary we discuss whether prophylactic aspirin therapy might be indicated in this patient population.
authors.affiliation: Radboud University Medical Centre, Department of Nephrology, Nijmegen, the Netherlands.
authors.forename: Julia M
authors.initials: JM
authors.lastname: Hofstra
authors.affiliation: Radboud University Medical Centre, Department of Nephrology, Nijmegen, the Netherlands. Electronic address: jack.wetzels@radboudumc.nl.
authors.forename: Jack F M
authors.initials: JFM
authors.lastname: Wetzels
mesh_terms: D000925:Anticoagulants; D001241:Aspirin; D015433:Glomerulonephritis, Membranous / Q000188:drug therapy*; D006801:Humans; D009404:Nephrotic Syndrome; D011322:Primary Prevention; D013927:Thrombosis
chemical_list: D000925:Anticoagulants; D001241:Aspirin